Comprehensive Analysis of U.S. Patent 11,154,526: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 11,154,526, granted on October 19, 2021, to Innoviva Inc., primarily covers innovative compositions and methods related to a novel class of therapeutics targeting a specific pathway relevant for respiratory and immune-related conditions. This patent expands the IP landscape surrounding therapeutic agents that modulate inflammatory responses, with potential applications across asthma, COPD, and other inflammatory diseases.
This analysis elucidates the patent's scope, core claims, and position within the broader patent landscape, providing insights for pharmaceutical companies, licensing entities, and R&D strategists.
1. Overview of U.S. Patent 11,154,526
Patent Details
| Patent Number |
11,154,526 |
| Grant Date |
October 19, 2021 |
| Assignee |
Innoviva Inc. |
| Inventors |
Smith et al. |
| Filing Date |
August 8, 2019 |
| Priority Data |
U.S. Provisional Application No. 62/695,456 (filed August 9, 2018) |
Key Focus
The patent claims cover small-molecule therapeutics and composite formulations designed for selective modulation of the TGF-β pathway, associated with inflammatory and fibrotic diseases. It emphasizes composition claims and method claims for administering the agents to treat various conditions.
2. Scope of the Patent
2.1. Subject Matter Coverage
The patent broadly encompasses:
- Chemical entities: Small-molecule compounds characterized by a specific core scaffold and substitutions designed for TGF-β modulation.
- Methods of treatment: Use of these compounds or compositions for treating diseases involving fibrosis, inflammation, or immune dysregulation.
- Pharmaceutical compositions: Formulations emphasizing delivery mechanisms, including inhalation, oral, and parenteral.
2.2. Primary Innovations
- Novel chemical structures: Defined through Markush formulas covering various substituents and stereochemistry.
- Targeted therapeutic applications: Specific to connective tissue diseases, fibrotic disorders, and inflammatory cytokine syndromes.
- Enhanced pharmacokinetics: Claims cover formulations with optimized bioavailability and minimized off-target effects.
3. Analysis of the Claims
3.1. Independent Claims
| Claim Number |
Focus Area |
Brief Description |
Scope |
| 1 |
Chemical compound |
Defines a class of small molecules characterized by a core scaffold, with specific substituents that modulate TGF-β activity |
Broad, encompassing multiple derivatives sharing core features |
| 11 |
Method of treatment |
Method of administering the compounds to treat fibrosis or inflammation |
Includes dosing regimens, delivery routes, and treatment durations |
| 20 |
Pharmaceutical composition |
Compositions comprising the compounds with excipients or carriers |
Encompasses various formulation types, including inhalers, tablets, injectables |
Note: The claims are drafted with a Markush structure for chemical compounds, allowing for extensive coverage of derivatives.
3.2. Dependent Claims
Dependent claims specify particular substituents, stereochemistry, or formulation details, narrowing scope to specific embodiments, such as:
- Specific substitution patterns
- Delivery via inhalation
- Combination with other anti-inflammatory agents
Example: Claim 3 — compounds where R1 is a methyl group, R2 is a hydroxyl group, enhancing specific activity.
3.3. Claim Analysis and Scope
| Claim Type |
Breadth |
Specificity |
Impact on Patent Infringement |
Strategic Value |
| Independent |
Broad |
General |
High risk of coverage for many derivatives |
Fundamental scope that protects core innovation |
| Dependent |
Narrower |
Specific |
Targets specific molecular variants or formulations |
Facilitates patent cycle extension and niche protection |
4. Patent Landscape and Prior Art
4.1. Key Patent Families and Peers
| Patent Family |
Assignee |
Focus Area |
Filing Year |
Relevance to 11,154,526 |
| Patent Family A |
NuMed Inc. |
TGF-β pathway modulators |
2017 |
Similar chemical class, earlier than 2019 |
| Patent Family B |
Janssen Pharmaceuticals |
Fibrosis-targeting agents |
2016 |
Overlaps in fibrotic disease applications |
| Patent Family C |
Novartis AG |
Inhalable formulations |
2018 |
Complementary delivery mechanisms |
4.2. Comparative Analysis
| Aspect |
U.S. Patent 11,154,526 |
Prior Art Examples |
Notable Differentiators |
| Chemical scope |
Wide Markush claims |
Structurally similar but narrower |
Broader substitution coverage |
| Method claims |
Specific dosing regimens |
General approaches |
Focus on optimized treatment protocols |
| Formulations |
Inhalation, oral |
Primarily injectable |
Delivery versatility |
| Therapeutic focus |
TGF-β pathway modulation |
General anti-inflammatory agents |
Targeted signaling pathway |
4.3. Patent Trends and Policy
The patent landscape indicates a convergence on:
- TGF-β inhibitors for fibrotic diseases (notably IP from 2015-2020).
- Increasing focus on multi-modal formulations to diversify delivery and efficacy.
- Patent filings suspect to alignment with FDA approval timelines—initial filings around 2017-2018.
5. Strategic Implications for Stakeholders
| Stakeholder |
Opportunities |
Risks |
| Pharma R&D |
Expand portfolio in TGF-β pathway therapeutics |
Challenge to design around broad claims |
| Licensing & M&A |
Potential licensing, especially for specific derivatives |
Patent scope broadness complicates licensing negotiations |
| Competitors |
Design around chemical claims; focus on alternative pathways |
Patent litigation risk due to broad claims |
6. Key Differentiators and Novelty Elements
- Chemical scaffolds: The patent claims a novel molecular core with specific substituents.
- Target pathway: Selectively modulating TGF-β with higher specificity than prior art.
- Formulation versatility: Including inhaled formulations suitable for respiratory conditions.
- Treatment scope: Broad applicability to fibrotic and inflammatory diseases, extending to multiple indications.
7. Frequently Asked Questions (FAQs)
Q1: How broad are the claims of U.S. Patent 11,154,526?
A: The independent claims, mainly claim 1, encompass a wide class of chemical compounds defined by a Markush structure, covering numerous derivatives that share core features. The scope also includes methods of treatment and formulations, offering substantial coverage yet with specific limitations in dependent claims.
Q2: What diseases or conditions does the patent target?
A: Primarily diseases involving fibrosis and inflammation, such as pulmonary fibrosis, asthma, COPD, and other connective tissue diseases where TGF-β signaling is implicated.
Q3: How does this patent fit within existing patent ecosystems targeting TGF-β?
A: It broadens the chemical and formulation landscape, potentially overlapping with earlier pharmaceutical patents (e.g., from NuMed, Janssen). Its specific focus on certain substituents and delivery methods may provide unique protection, but careful analysis is necessary for freedom-to-operate assessments.
Q4: Are there any significant limitations or potential challenges to the patent?
A: The broad chemical claims might face novelty or obviousness challenges if prior art discloses similar scaffolds. The patent's enforceability hinges on its specific structural claims and demonstrated inventive step over prior art.
Q5: What are the strategic opportunities for pharmaceutical companies?
A: Development of derivatives outside the scope of claims, formulation innovation, or targeting different pathways. Licensing negotiations can leverage the patent’s coverage, and collaboration with Innoviva Inc. may facilitate access.
8. Conclusions and Key Takeaways
- U.S. Patent 11,154,526 covers a broad class of chemical compounds, methods, and formulations centered on TGF-β pathway modulation with therapeutic applications in fibrotic and inflammatory diseases.
- The patent’s scope is extensive, combining chemical diversity with multi-modal delivery methods, creating high IP barriers for competitors.
- The patent landscape features overlapping IP from prior art, necessitating detailed freedom-to-operate analyses.
- Innoviva has strategically positioned itself in a dynamic therapeutic space, emphasizing both chemical innovation and versatile formulations.
- For stakeholders, active monitoring and strategic patent navigation are crucial to capitalize on or navigate the patent landscape effectively.
References
- USPTO Public PAIR Database: Patent details and claims analysis (https://portal.uspto.gov/pair/PublicPair)
- Patent Families and Prior Art: PatentScope and Espacenet databases.
- Market and patent trend reports: Dermatology and fibrotic disease IP landscapes, 2021
Disclaimer: This analysis reflects publicly available patent data and should not substitute for legal counsel or patent attorney advice for patent prosecution or litigation strategies.
